AbbVie Inc. (ABBV)

74.54
0.04 0.05
NYSE : Health Technology
Prev Close 74.50
Open 74.38
Day Low/High 74.34 / 74.98
52 Wk Low/High 62.66 / 94.98
Volume 3.10M
Avg Volume 8.68M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 109.05B
EPS 3.70
P/E Ratio 26.25
Div & Yield 4.28 (5.66%)
It's Not Just the Fed: Cramer's 'Mad Money' Recap (Monday 7/8/19)

It's Not Just the Fed: Cramer's 'Mad Money' Recap (Monday 7/8/19)

Jim Cramer says investors may be misreading the Fed and the moment, but he's got your game plan for earnings season.

Starbucks, General Electric, AbbVie: 'Mad Money' Lightning Round

Starbucks, General Electric, AbbVie: 'Mad Money' Lightning Round

Jim Cramer checks in on Starbucks, General Electric, AbbVie, Adaptive Biotechnologies, Vector Group, PBF Energy and more.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

What's the Difference Between Indica vs. Sativa?

What's the Difference Between Indica vs. Sativa?

Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?

ABBV: Insiders Vs. Shorts

ABBV: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and AbbVie Inc is the #122 most shorted of the S&P 500 components, based on 5.57 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential

AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential

AbbVie's deal for Allergan will give it a new revenue stream in Botox, helping offset potential lower revenue from arthritis drug Humira, which is losing patent protection.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Replay: What to Watch in The Markets: AbbVie-Allergan, Micron, Buffett, and More

Replay: What to Watch in The Markets: AbbVie-Allergan, Micron, Buffett, and More

The ActionAlertsPLUS team breaks down what investors need to know on Tueday, including: AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.

Getting Nervous

After days of complacency, we see a shift in sentiment and folks are getting the jitters.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Allergan Plc

SHAREHOLDER ALERT: WeissLaw LLP Investigates Allergan Plc

NEW YORK, June 25, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Allergan Plc ("Allergan" or the "Company") (NYSE: AGN) in connection with the proposed...

5 Blockbuster M&A Deals of 2019

5 Blockbuster M&A Deals of 2019

AbbVie takes over Allergan. But, it's not the biggest deal of 2019...

Dow Ends Lower, Stocks Fall as Powell Says Fed 'Grappling' with Rate Cut

Dow Ends Lower, Stocks Fall as Powell Says Fed 'Grappling' with Rate Cut

Major indexes declined Tuesday after Federal Reserve Chairman Jerome Powell hedged on a possible rate cut.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

AbbVie Buys Allergan for $63 Billion: Was the Price Just Right?

AbbVie Buys Allergan for $63 Billion: Was the Price Just Right?

AbbVie to purchase botox maker Allergan in $63 billion deal, but is the price just right?

Allergan Agrees to $63 Billion Takeover From AbbVie in Blockbuster Pharma Deal

Allergan Agrees to $63 Billion Takeover From AbbVie in Blockbuster Pharma Deal

Allergan shares surged the most in more than 25 years Tuesday after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie .

I Believe AbbVie and Allergan Need Each Other

I Believe AbbVie and Allergan Need Each Other

With no other bidder expected to emerge, this is a high risk arbitrage play.

Shares of Botox Maker Allergan Get a Lift

Shares of Botox Maker Allergan Get a Lift

AbbVie is Real Money's Stock of the Day. The biopharmaceutical giant announced a planned $63 billion takeover of Allergan. Action Alerts PLUS Senior Portfolio Analyst Jeff Marks breaks down what investors need to know about the deal.

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

PFE was ready to pay $160 billion until U.S. regulators blocked the deal.

Another Day, Another Deal: What to Watch from AbbVie, Allergan, Micron, Buffett

Another Day, Another Deal: What to Watch from AbbVie, Allergan, Micron, Buffett

Wall Street woke up to another major deal. Here's what to watch from AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement

AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement

Let's look closer at the charts and indicators of ABBV.

Dow Futures Flat, Dollar Sips as Trade Concerns Trim Risk Appetite Ahead of G20

Dow Futures Flat, Dollar Sips as Trade Concerns Trim Risk Appetite Ahead of G20

U.S. equity futures drifted lower Tuesday, setting up the S&P 500 for its first three-day decline since early May, as investors peel back from recent record highs and take a defensive stance on risk ahead of this weekend's G20 Summit in Japan.

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.

Micron, FedEx, Trump-Xi, Tesla and Amazon - 5 Things You Must Know

Micron, FedEx, Trump-Xi, Tesla and Amazon - 5 Things You Must Know

U.S. stock futures decline as investors take a defensive stance on risk ahead of this weekend's G-20 summit in Japan; Micron reports earnings Tuesday; FedEx, which also reports earnings, sues the U.S. government arguing new trade regulations put an 'impossible burden' on the company to monitor its shipments.

AbbVie To Acquire Allergan In Transformative Move For Both Companies

AbbVie To Acquire Allergan In Transformative Move For Both Companies

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

AbbVie Announces US FDA Lifts Partial Clinical Hold On Phase 3 Study Of Venetoclax In Patients With Multiple Myeloma Positive For The T(11;14) Genetic Abnormality

AbbVie Announces US FDA Lifts Partial Clinical Hold On Phase 3 Study Of Venetoclax In Patients With Multiple Myeloma Positive For The T(11;14) Genetic Abnormality

- FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 20, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc.

TheStreet Quant Rating: C (Hold)